Pathogenesis of tubulointerstitial fibrosis in chronic allograft dysfunction

Clinical Transplantation

Volumn 23, Issue SUPPL.21, 2009, Pages 26-32

  Strutz, Frank ^a  

^a Division of Gastroenterology   (Germany)

Author keywords

EMT; Extracellular matrix; Fibroblast

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BONE MORPHOGENETIC PROTEIN; CALVASCULIN; CYCLOSPORIN A; HEAT SHOCK PROTEIN 47; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ONCOSTATIN M; PROTEIN S 100; RAPAMYCIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CHRONIC ALLOGRAFT NEPHROPATHY; DISEASE CLASSIFICATION; DOWN REGULATION; FIBROGENESIS; HUMAN; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; MESENCHYME CELL; MYOFIBROBLAST; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENOVASCULAR HYPERTENSION; REVIEW; SURVIVAL RATE; UPREGULATION;

EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; MESENCHYMAL STEM CELLS;

EID: 70649101510     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01106.x     Document Type: Review

References (51)

1. Paul LC. Chronic renal transplant loss. Kidney Int 1995, 47:1491.
2. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005, 16:3015.
3. Joosten SA, van Kooten C, Sijpkens YW, de Fijter JW, Paul LC. The pathobiology of chronic allograft nephropathy: immune-mediated damage and accelerated aging. Kidney Int 2004, 65:1556.
4. Afzali B, Taylor AL, Goldsmith DJ. What we CAN do about chronic allograft nephropathy: role of immunosuppressive modulations. Kidney Int 2005, 68:2429.
5. Racusen LC, Solez K, Colvin RB. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999, 55:713.
6. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003, 349:2326.
7. Solez K, Colvin RB, Racusen LC. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007, 7:518.
8. Müller GA, Zeisberg M, Strutz F. The importance of tubulointerstitial damage in progressive renal disease. Nephrol Dial Transplant 2000, 15(Suppl. 6):76.
9. Freese P, Svalander CT, Molne J, Norden G, Nyberg G. Chronic allograft nephropathy - biopsy findings and outcome. Nephrol Dial Transplant 2001, 16:2401.
10. Cosio FG, Grande JP, Larson TS. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant 2005, 5:1130.
11. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005, 5:2464.
12. Strutz F, Zeisberg M. Renal fibroblasts and myofibroblasts in chronic kidney disease. J Am Soc Nephrol 2006, 17:2992.
13. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol 2007, 170:1807.
14. Strutz F, Okada H, Lo CW. Identification and characterization of fibroblast-specific protein 1 (FSP1). J Cell Biol 1995, 130:393.
15. Okada H, Danoff TM, Fischer A, Lopez-Guisa JM, Strutz F, Neilson EG. Identification of a novel cis-acting element for fibroblast-specific transcription of the FSP1 gene. Am J Physiol 1998, 275(2 Pt 2):F306.
16. Iwano M, Fischer A, Okada H. Conditional abatement of tissue fibrosis using nucleoside analogs to selectively corrupt dna replication in transgenic fibroblasts. Mol Ther 2001, 3:149.
17. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002, 110:341.
18. Ikeda Y, Jung YO, Kim H. Exogenous bone morphogenetic protein-7 fails to attenuate renal fibrosis in rats with overload proteinuria. Nephron Exp Nephrol 2004, 97:e123.
19. Faulkner JL, Szcykalski LM, Springer F, Barnes JL. Origin of interstitial fibroblasts in an accelerated model of angiotensin II-induced renal fibrosis. Am J Pathol 2005, 167:1193.
20. Okada H, Ban S, Nagao S, Takahashi H, Suzuki H, Neilson EG. Progressive renal fibrosis in murine polycystic kidney disease: an immunohistochemical observation. Kidney Int 2000, 58:587.
21. Yang J, Shultz RW, Mars WM. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 2002, 110:1525.
22. Pollack V, Sarkozi R, Banki Z. Oncostatin M-induced effects on EMT in human proximal tubular cells: differential role of ERK signaling. Am J Physiol Renal Physiol 2007, 293:F1714.
23. Vongwiwatana A, Tasanarong A, Rayner DC, Melk A, Halloran PF. Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am J Transplant 2005, 5:1367.
24. Robertson H, Ali S, McDonnell BJ, Burt AD, Kirby JA. Chronic renal allograft dysfunction: the role of T cell-mediated tubular epithelial to mesenchymal cell transition. J Am Soc Nephrol 2004, 15:390.
25. Hertig A, Verine J, Mougenot B. Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 2006, 6:2937.
26. Shimizu A, Yamada K, Sachs DH, Colvin RB. Persistent rejection of peritubular capillaries and tubules is associated with progressive interstitial fibrosis. Kidney Int 2002, 61:1867.
27. Bonsib SM, Abul-Ezz SR, Ahmad I. Acute rejection-associated tubular basement membrane defects and chronic allograft nephropathy. Kidney Int 2000, 58:2206.
28. Hoffmann SC, Hale DA, Kleiner DE. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 2005, 5:573.
29. Zeisberg M, Yang C, Martino M. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007, 282:23337.
30. Rygiel KA, Robertson H, Marshall HL. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest 2008, 88:112.
31. Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2007, 293:L525.
32. Zeisberg EM, Tarnavski O, Zeisberg M. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007, 13:952.
33. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008, 19:2282.
34. Strutz F. How many different roads may a cell walk down in order to become a fibroblast?. J Am Soc Nephrol 2008, 19:2246.
35. Desmoulière A, Gabbiani G. Myofibroblast differentiation during fibrosis. Exp Nephrol 1995, 3:134.
36. Wallach-Dayan SB, Golan-Gerstl R, Breuer R. Evasion of myofibroblasts from immune surveillance: a mechanism for tissue fibrosis. Proc Natl Acad Sci USA 2007, 104:20460.
37. Jelaska A, Korn JH. Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000, 43:2230.
38. Liptak P, Ivanyi B. Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol 2006, 2:398.
39. McMorrow T, Gaffney MM, Slattery C, Campbell E, Ryan MP. Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. Nephrol Dial Transplant 2005, 20:2215.
40. Copeland JW, Beaumont BW, Merrilees MJ, Pilmore HL. Epithelial-to-mesenchymal transition of human proximal tubular epithelial cells: effects of rapamycin, mycophenolate, cyclosporin, azathioprine, and methylprednisolone. Transplantation 2007, 83:809.
41. Flechner SM. Minimizing calcineurin inhibitor drugs in renal transplantation. Transplant Proc 2003, 35(3 Suppl.):118S.
42. Flechner SM, Goldfarb D, Solez K. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007, 83:883.
43. Larson TS, Dean PG, Stegall MD. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006, 6:514.
44. Rintala JM, Savikko J, Rintala SE, von Willebrand E. The effect of leflunomide analogue FK778 on development of chronic rat renal allograft rejection and transforming growth factor-BETA expression. Transplant Proc 2006, 38:3239.
45. Lutz J, Huang H, Deng M. The effect of FK778 on the progression of chronic allograft nephropathy in a rat model. Transplantation 2007, 83:741.
46. Hruska KA, Guo G, Wozniak M. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol 2000, 279:F130.
47. Zeisberg M, Hanai J, Sugimoto H. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003, 9:964.
48. Zeisberg M, Bottiglio C, Kumar N. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol 2003, 285:F1060.
49. Tyler JR, Robertson H, Booth TA, Burt AD, Kirby JA. Chronic allograft nephropathy: intraepithelial signals generated by transforming growth factor-beta and bone morphogenetic protein-7. Am J Transplant 2006, 6:1367.
50. Yang J, Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 2002, 13:96.
51. Croce CM. Oncogenes and cancer. N Engl J Med 2008, 358:502.